Certain Stock Options of Twist Bioscience Corporation are subject to a Lock-Up Agreement Ending on 4-OCT-2026.
Certain Stock Options of Twist Bioscience Corporation are subject to a lock-up agreement that ends on October 4, 2026. The lock-up period for these options began on August 4, 2026, and lasts for 61 days. During this time, the company's executive officers and directors are restricted from offering, selling, disposing of, or hedging any shares of common stock or convertible securities, with some exceptions.
Form 144 Twist Bioscience Corp For: 2 October By Investing.com
This article from Investing.com announces the filing of Form 144 for Twist Bioscience Corp on October 2. The brief piece includes the stock symbol TWST and indicates a slight positive change in its price at the time of publication.
An officer proposes selling vested shares at Twist Bioscience (TWST), partly to cover an equity-award tax obligation.
An officer at Twist Bioscience (TWST), Patrick Finn, has proposed selling 25,714 common shares with an aggregate market value of $4,856,958.03, primarily to cover a tax obligation from vested equity awards. The shares stem from restricted stock vesting on October 1, 2026, with an approximate sale date of October 2, 2026. This filing also details previous sales by Finn in July and August 2026.
An officer proposes selling 1,482 Twist Bioscience (TWST) shares, including shares to cover taxes.
Robert F. Werner, an officer at Twist Bioscience Corp. (TWST), has proposed selling 1,482 common shares with an aggregate market value of $279,925.79, primarily to cover tax obligations from a vested equity award distribution. The shares were acquired through restricted stock vesting on October 1, 2026, with the approximate sale date set for October 2, 2026, through Fidelity Brokerage Services LLC. This Form 144 filing indicates a neutral impact and sentiment, as it is a routine sale to manage tax liabilities associated with equity compensation.
An officer's proposed sale at Twist Bioscience (TWST) includes shares to cover an equity-award tax bill.
Twist Bioscience officer Dennis H. Cho has proposed selling 9,514 common shares, valued at approximately $1.8 million, with the sale scheduled for October 2, 2026. This proposed sale includes shares intended to cover a tax obligation arising from a vested equity award distribution. The shares were acquired through restricted stock vesting on October 1, 2026.
Form 144 Twist Bioscience Corp For: 2 October By Investing.com
This article reports on the filing of Form 144 by Twist Bioscience Corp on October 2. Form 144 indicates an intent to sell restricted securities. The brief article, published by Investing.com, provides no further details beyond the company name, filing type, and date.
Twist Bioscience (TWST) Stock Could Be Reasonable On Its 9x Three Year Run
Twist Bioscience (TWST) has seen a significant 9x gain over the past three years, prompting questions about whether its current share price of around US$188 is justified by its cash flows. A new collaboration with Eli Lilly's TuneLab, integrating Twist Bioscience's antibody data services with an AI-driven discovery platform, is expected to accelerate its technology's conversion into contracted work and cash generation. Despite a current free cash outflow, the Discounted Cash Flow model suggests the stock's intrinsic value is modestly above its trading price, contingent on a future shift to positive cash generation, while some community narratives on Simply Wall St suggest the stock might be overvalued.
Revenue per share of Twist Bioscience Corp. – HAN:0ME
This article provides financial information for Twist Bioscience Corp. (HAN:0ME) listed on the Hannover Stock Exchange, specifically focusing on its revenue per share. It appears to be a page from a financial data platform, displaying basic trading information and historical data, but without specific figures in the provided content.
Diluted shares outstanding of Twist Bioscience Corp. – HAN:0ME
This article provides financial data for Twist Bioscience Corp. (HAN:0ME) regarding its diluted shares outstanding. The information is presented within the context of the Hannover Stock Exchange. The content highlights a specific financial metric for the company.
What Twist Bioscience (TWST)'s Lilly TuneLab Deal Means For Shareholders
Twist Bioscience's agreement with Lilly TuneLab integrates its antibody characterization services into Eli Lilly's AI drug discovery platform, which could deepen relationships with pharmaceutical companies and generate recurring revenue. While this deal supports the demand for Twist's services, the company still faces challenges with adjusted EBITDA losses and cash burn. The success of this collaboration hinges on Twist's ability to convert access into consistent, high-quality service demand to meet revenue growth targets and achieve profitability.
Quick ratio of Twist Bioscience Corp. – HAN:0ME
This article focuses on the quick ratio of Twist Bioscience Corp. (HAN:0ME) as displayed on TradingView. It appears to be a stub or a page with minimal content, primarily outlining the company's stock exchange listing and basic financial data availability. The page emphasizes that financial data is provided by ICE Data Services and FactSet.
TWST Maintained by Leerink Partners -- Price Target Raised to $1
Leerink Partners has maintained an "Outperform" rating on Twist Bioscience (TWST) and increased its price target to $190 from $160. Despite this positive analyst outlook, GuruFocus indicates that TWST is significantly overvalued with a GF Value™ of $53.64 against a current price of $182.72, and shows a moderate overall performance with a GF Score™ of 68/100 due to strong growth but weak profitability and valuation. Insider selling activity also suggests caution for potential investors.
Form 144 Twist Bioscience Corp For: 28 September By Investing.com
This article reports on the filing of Form 144 for Twist Bioscience Corp (TWST) on September 28, 2026. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider trading activity. The brief announcement provides no further details beyond the company name and filing date.
Twist Bioscience: Don't Confuse A Short Squeeze With An AI Revolution (NASDAQ:TWST)
Twist Bioscience (TWST) has seen a significant surge in market capitalization from $1.7 billion to $12 billion, primarily due to multiple expansion, short covering, and AI enthusiasm, rather than substantial fundamental growth. The article argues that TWST's AI opportunity is overstated, with AI-related revenue projected to be a minority of total revenue in FY26 and FY27. Despite some fundamental improvements and raised guidance, the company's valuation at ~26x sales is deemed software-like for what is essentially a manufacturing/services business.
Twist Bioscience Corp (Derivatives) Price History and Historical Data
This page from CoinMarketCap provides access to the price history and historical data for Twist Bioscience Corp (Derivatives). It is primarily a navigational page with various links to market data, cryptocurrencies, exchanges, community features, API documentation, products, and educational resources related to CoinMarketCap's offerings.
Twist Bioscience Corp (Derivatives) price today, TWST to USD live price, marketcap and chart
This article provides live price data for Twist Bioscience Corp (Derivatives) (TWST), showing its current price of $181.81 and a 0.97% increase in the last 24 hours. It details market statistics such as a 24-hour low of $177.60 and a high of $187.03, along with its all-time high and low recorded on September 28, 2026. The page also lists other tokenized assets and popular cryptocurrencies.
Twist Bioscience Corporation (TWST) Stock Price, News, Quote & History
This article provides comprehensive financial data for Twist Bioscience Corporation (TWST), including its stock price, historical performance, key financial metrics, and analyst insights. The company, which specializes in synthetic DNA-based products for various applications, has shown significant stock appreciation year-to-date and over the past year. Detailed information on its products, collaborations, and recent earnings trends are also presented.
Twist Bioscience SVP Paula Green sells $48,654 in common stock
Paula Green, SVP of Human Resources at Twist Bioscience Corp. (NASDAQ:TWST), sold 294 shares of common stock for $48,654 on September 21, 2026. This transaction was a mandatory "sell to cover" to satisfy tax withholding obligations related to Restricted Stock Units, not a discretionary trade. Following the sale, Ms. Green still holds 116,720 shares, while the company's stock trades near its 52-week high after a significant return over the past year.
Twist Bioscience CEO Emily Leproust sells $279,183 in stock
Emily Leproust, CEO of Twist Bioscience (NASDAQ:TWST), sold 1,687 shares of company stock worth $279,183 to cover tax withholding obligations from vested Restricted Stock Units. This "sell to cover" transaction is mandated by the company's equity incentive plans and is not a discretionary trade. The sale occurred while TWST stock has seen a 579% surge over the past year and trades near its 52-week high, although InvestingPro analysis indicates the stock may be overvalued.
Form 4 Twist Bioscience Corp For: 27 September By Investing.com
This article from Investing.com announces the filing of Form 4 for Twist Bioscience Corp on September 27. It appears to be a very brief notification without additional details, possibly serving as an alert for market participants interested in insider transactions or corporate filings.
Twist Bioscience Stock Jumped 16% Thursday. Leerink Says Anthropic Made It Happen.
Twist Bioscience (TWST) stock surged 16% after Leerink Partners increased its price target to $160 and highlighted the company as a key beneficiary of Anthropic's expanding biology research. Anthropic is funding the testing of 5,000 protein designs using Twist Bioscience's synthetic DNA, with Claude analyzing the data rapidly. This news, coupled with a recent deal with Eli Lilly for AI-driven drug discovery, indicates Twist Bioscience's crucial role as an infrastructure provider for AI in biological research.
Under a June trading plan, Twist Bioscience (TWST) CEO Emily M. Leproust sold 5,203 shares in 10 transactions.
Twist Bioscience CEO Emily M. Leproust sold 5,203 shares of common stock across ten transactions on September 24, 2026. These sales were executed under a Rule 10b5-1 trading plan established on June 15, 2026. The transactions involved varying quantities of shares at weighted-average prices ranging from $175.2313 to $184.6030 per share.
Twist Bioscience Stock Hits New High, Then Retreats: What's Happening?
Twist Bioscience (NASDAQ: TWST) shares hit a new 52-week high of $192 before pulling back to $183. This follows a nine-week rally where the stock gained over 100%, characterized by distinct rally legs followed by 10-15% pullbacks. The current retreat aligns with this pattern, suggesting profit-taking and reaccumulation rather than an end to the upward trend, though the extended duration of new highs without consolidation is noted.
Twist Bioscience Corporation Stock Analysis: Bullish Momentum Meets Overbought Risks
Twist Bioscience Corporation's stock surged 16.1% to $184.03, driven by a partnership with Lilly TuneLab, pushing it into overbought territory with daily RSI at 74.39. While the trend is strongly bullish across all timeframes, indicators suggest overextension and potential for a pullback, necessitating cautious risk management. Key support levels are identified at $175.36 and $165.50, with analysts' price targets currently below the trading price.
Twist Bioscience Stock Jumped 16% Thursday. Leerink Says Anthropic Made It Happen.
Twist Bioscience (TWST) stock surged 16% after Leerink Partners raised its price target, citing the company as a key beneficiary of Anthropic's expanding biology research. Leerink highlighted Anthropic's use of Twist Bioscience's synthetic DNA for protein design testing, with Claude analyzing lab data rapidly. This move, along with a recent deal with Eli Lilly, positions Twist Bioscience as critical infrastructure for AI drug discovery, outperforming market expectations and analyst price targets.
Twist Bioscience stock hits 52-week high at 170.69 USD
Twist Bioscience (TWST) stock reached a new 52-week high of $170.69, reflecting a 527.55% increase over the past year and a market capitalization of $10.54 billion. Despite its strong performance, InvestingPro analysis suggests the stock is currently overvalued with an overbought RSI. The company recently partnered with Lilly TuneLab for AI/ML drug discovery and received both a "sell" rating from BWS Financial due to valuation concerns and a "Buy" rating from Guggenheim, while also facing scrutiny from short seller Scorpion Capital regarding its AI partnership claims.
A proposed share sale valued at $922,906 names Emily M. Leproust as the Twist Bioscience (TWST) account holder.
A Form 144 notice indicates that Emily M. Leproust, an officer and director of Twist Bioscience (TWST), proposes to sell 5,203 common shares valued at approximately $922,906 through Fidelity Brokerage Services LLC, with an approximate sale date of September 24, 2026. The filing also details previous sales, including 356,546 common shares sold on September 17, 2026, for over $56 million. These shares largely originated from restricted stock vesting on various dates.
Twist Bioscience Corp Stock (TWST) Moved Up by 11.04% on Sep 24: A Full Analysis
Twist Bioscience Corp (TWST) saw an 11.04% stock increase on September 24, driven by a strategic collaboration with Eli Lilly, integrating Twist's data services into Lilly's AI-driven drug discovery platform. This partnership, coupled with strong third-quarter financial results showing double-digit revenue growth and improved margins, has generated significant investor interest and positive analyst sentiment. Despite this growth, the company faces risks such as persistent net losses, a high valuation, and recent insider share liquidations.
Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal
Twist Bioscience (TWST) stock jumped over 8% following an agreement to provide antibody characterization data and services to Eli Lilly’s AI/ML drug discovery platform, TuneLab. This partnership feeds high-quality lab data into Lilly's AI models, boosting investor optimism around the AI collaboration theme. Leerink raised its price target for TWST from $120 to $160, citing a large, early-stage AI drug discovery opportunity.
Twist Bioscience Corporation (TWST) stock price, news, quote and history
This article provides a comprehensive overview of Twist Bioscience Corporation (TWST), including its current stock price, financial data, and company profile. It details the company's biotechnology products, market performance, and analyst ratings. The report also includes historical data, earnings trends, and key statistics for investors.
Twist Bioscience Slides as Recent Rally Cools and CEO Sale Filing Weighs on Sentiment
Twist Bioscience (TWST) shares fell 3.8% due to profit-taking after a recent rally and news of CEO Emily Leproust's planned share sale. Despite no negative operational updates, the stock's valuation near its 52-week high made it susceptible to a pullback. The decline follows a strong rally driven by a new partnership with Lilly TuneLab announced on September 16.
Twist Bioscience (TWST) CEO trades 356K shares at up to $163.60
Twist Bioscience (TWST) CEO Emily M. Leproust exercised employee stock options and sold 356,546 common shares on September 17, 2026, under a Rule 10b5-1 trading plan. The sales occurred at weighted average prices ranging from approximately $150.77 to $163.60. Following these transactions, Ms. Leproust continues to hold significant employee stock options and common stock in the company.
Twist Bioscience (TWST) Expands AI Drug Discovery Exposure With Lilly TuneLab Partnership
Twist Bioscience (TWST) has partnered with Lilly TuneLab, a platform by Eli Lilly and Company (LLY), to provide antibody characterization data services for AI-driven drug discovery. This collaboration positions Twist to benefit from the growing AI drug discovery ecosystem by supplying high-quality experimental data and services. While the partnership strengthens Twist's exposure to AI in drug development, the near-term financial impact is uncertain as no specific revenue commitments have been disclosed.
Form 144 Twist Bioscience Corp For: 22 September By Investing.com
The article reports that Twist Bioscience Corp filed a Form 144 on September 22. It provides no further details about the filing but lists the company's stock symbol (TWST) and its current performance. The content primarily consists of navigation links and market data, with the core article being just a single sentence.
After $1.8M stock sale, Twist Bioscience (NASDAQ: TWST) insider files to sell more
An officer at Twist Bioscience (TWST) has filed a Rule 144 notice to sell 348 shares valued at $57,591.01, partly to cover tax obligations from vested equity awards. This planned sale follows several prior large sales by the same officer, Dennis H. Cho, totaling over $4.7 million in the preceding three months. The filing provides details on the acquisition of shares through restricted stock vesting and outlines previous transactions.
After $56M sale, Twist Bioscience (NASDAQ: TWST) insider plans more
Emily M. Leproust, an insider at Twist Bioscience (TWST), plans to sell 1,687 shares of common stock valued at $279,183.99 through Fidelity Brokerage Services LLC. This planned sale follows significant insider sales in recent months, including a $56 million sale on September 17, 2026. The current sale includes shares to cover a tax obligation from a vested equity award.
Twist Bioscience Corporation - Common Stock (NQ: TWST
This article provides recent news headlines and financial updates concerning Twist Bioscience Corporation (TWST). Key information includes upcoming earnings reports, analyst upgrades, product expansions, and executive appointments. The company's stock performance and various news sources are also highlighted.
TWST Surges As Twist Bioscience Wins Eli Lilly AI Deal
Twist Bioscience Corporation (TWST) shares surged by 7.1% following an agreement to provide antibody characterization data services to Eli Lilly's AI-driven TuneLab drug discovery platform. This deal integrates Twist Bioscience's wet-lab data directly into Lilly's AI/ML models, linking TWST to the significant AI drug discovery theme. Analysts at Leerink raised TWST's price target to $160, while UBS initiated coverage with a $144 target, highlighting the company's strong position in the life science tools sector despite ongoing profitability challenges.
Twist Bioscience TWST Jumps On Lilly AI Drug Discovery Deal
Twist Bioscience (TWST) shares jumped by 9.74% following a new agreement with Eli Lilly’s AI-driven TuneLab drug discovery platform, where TWST will provide antibody characterization data. This deal strengthens Twist Bioscience's role in AI-enabled biologics discovery and comes as the company reports its 14th consecutive quarter of revenue growth, reaching $118.4M in Q3 FY26, with full-year guidance raised. Despite still facing negative profit margins and a high price-to-sales ratio, the company is nearing adjusted EBITDA breakeven and is being watched by traders due to strong catalysts in AI and biotech.
Twist Bioscience (TWST) Is Up 14.0% After Lilly AI Drug Discovery Tie-Up Is Announced - Has The Bull Case Changed?
Twist Bioscience (TWST) saw a 14.0% stock increase following its announced agreement with Lilly TuneLab, where Twist will provide antibody characterization data for Lilly's AI/ML drug discovery models. This collaboration integrates Twist's DNA and antibody capabilities into Lilly's AI ecosystem, potentially strengthening Twist's role in AI-enhanced antibody development. Despite this positive development, the article notes that it doesn't resolve Twist's ongoing losses or dependence on a few large customers, raising questions about its path to profitability and the impact of recent equity dilution on its investment narrative.
Twist Bioscience stock rises on Eli Lilly partnership deal
Twist Bioscience Corp (NASDAQ:TWST) shares climbed 3% following the announcement of a partnership with Eli Lilly and Company's TuneLab. Under the agreement, Twist will provide antibody characterization data services for TuneLab, aiming to accelerate biotech innovation by connecting experimental data with AI-enabled drug discovery. This collaboration will allow TuneLab users to access Twist's services with preferred protocols and pricing, contributing to more efficient antibody drug discovery.
Cathie Wood’s ARK sells Twist Bioscience stock, buys more Intellia
Cathie Wood's ARK Investment Management has significantly reshuffled its portfolio by selling shares in Twist Bioscience Corporation, 10X Genomics, Inc., Bullish, Tempus AI, Inc., GeneDx Holdings Corp., and Alphabet Inc. Concurrently, ARK continued to increase its stake in Intellia Therapeutics, Inc., reflecting a strategic reallocation of its investments. These moves highlight ARK's ongoing strategy to adjust its holdings to capitalize on new opportunities and trim positions in other companies.
Twist Bioscience HR SVP Paula Green Sells Shares to Cover RSU Tax Withholding
Paula Green, Senior Vice President of Human Resources at Twist Bioscience Corp, sold 907 shares of company common stock on September 8, 2026. This transaction, valued at $122.624 per share, was not a discretionary trade but a mandatory "sell to cover" sale to meet tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs). After the sale, Green directly holds 117,014 shares of Twist Bioscience.
Twist Bioscience to Present at Baird 2026 Global Healthcare Conference
Twist Bioscience Corporation announced that its CEO, Emily M. Leproust, Ph.D., and CFO, Adam Laponis, will participate in a fireside chat at the Baird 2026 Global Healthcare Conference. The event is scheduled for September 15, 2026, at 1:25 pm Eastern Time in New York City, and will be webcast live on the company's investor relations website. A replay will be available for 30 days following the event.
BWS Financial initiates Twist Bioscience stock with sell rating By Investing.com
BWS Financial has initiated coverage on Twist Bioscience (NASDAQ:TWST) with a "sell" rating and a price target of $45.00, citing its significant premium over peers in a competitive market and operational ceiling for gross margin. Despite a remarkable 410% return over the past year, the company is not expected to be profitable this year. This contrasts with a recent revenue beat in Q3 2026 and a "Buy" rating from Guggenheim.
BWS Financial initiates Twist Bioscience stock with sell rating
BWS Financial initiated coverage on Twist Bioscience (NASDAQ:TWST) with a sell rating and a price target of $45.00, citing its significant premium compared to competitors and overvaluation. Analyst Hamed Khorsand highlighted pricing pressure from integrated incumbents, the non-commercial nature of a recent stock-driving research evaluation, and increasing insider selling. Despite a remarkable stock performance over the past year, the company is not expected to be profitable this year.
Twist Bioscience to Present at Baird 2026 Global Healthcare Conference
Twist Bioscience announced that its CEO, Emily M. Leproust, Ph.D., and CFO, Adam Laponis, will participate in a fireside chat at the Baird 2026 Global Healthcare Conference. The event is scheduled for September 15, 2026, at 1:25 pm Eastern Time in New York City and will be webcast live. A replay of the chat will be available for 30 days on the company's investor relations website.
Claim your share of the $17 million Twist Bioscience securities class action settlement
Investors who purchased Twist Bioscience common stock between December 20, 2018, and November 15, 2022, or in its December 2020 secondary offering, may be eligible for a cash payment from a $17 million securities class action settlement. The lawsuit alleged that Twist Bioscience made false and misleading statements about its production process, product quality, and accounting, leading to inflated stock prices and investor losses. Eligible class members must submit a claim by November 17, 2026, with the estimated average net recovery being $0.22 per affected share.
Cathie Wood’s ARK sees major stock moves with Robinhood and Twist Bioscience By Investing.com
Cathie Wood's ARK ETFs made several significant trades on Friday, September 4th, 2026, increasing its stake in Robinhood Markets, Veracyte, and Intellia Therapeutics. Conversely, ARK reduced its positions in Twist Bioscience Corporation and Tempus AI. These moves reflect ARK's continued focus on technology, healthcare, and innovation.
Twist Bioscience Corp (TWST) Stock Up 7.5% but GF Value Says Overvalued -- GF Score: 69/100
Twist Bioscience Corp (TWST) stock rose 7.5% today to $151.42, yet GuruFocus's GF Value™ indicates it is 188.0% overvalued compared to its fair value of $52.58. The company shows strong growth (10/10) but struggles with profitability (3/10) and is considered highly overvalued (1/10). Notably, insiders have sold $64.5M worth of shares over the past year with no buying activity, raising concerns about future prospects.
